SSR182289A, a Selective and Potent Orally Active Thrombin InhibitorAltenburger · Bioorganic & Medicinal Chemistry2004PDF618 KB
Antithrombotic Properties of SSR182289A, a New, Orally Active Thrombin InhibitorLorrain · Journal of Pharmacology and Experimental Therapeutics2003PDF169 KB
Binding Characteristics of SSR180575, a Potent and Selective Peripheral Benzodiazepine LigandVin · Biochemical and Biophysical Research Communications2003PDF141 KB
A76A THE ??7nACh RECEPTOR AGONIST, SSR180711, DISPLAYS ANTIDEPRESSANT-LIKE EFFECTS IN RODENTSStemmelin · Behavioural Pharmacology2005PDF164 KB
SSR182289A, a Novel, Orally Active Thrombin Inhibitor: In Vitro Profile and ex Vivo Anticoagulant ActivityBerry · Journal of Pharmacology and Experimental Therapeutics2002PDF476 KB
SSR182289A Enhances Thrombolysis Induced by Fibrinolytic Agents in Rabbit Models of Venous and Arterial ThrombosisVisconte · Journal of Thrombosis and Haemostasis2004PDF159 KB
SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (1) Binding and Functional ProfileBiton · Neuropsychopharmacology2006PDF588 KB
Synthesis and in Vitro Characterization of Novel Fluorinated Derivatives of the TSPO 18 kDa Ligand SSR180575Damont · European Journal of Medicinal Chemistry2015PDF862 KB
SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. I: Neurochemical and Electrophysiological ProfileClaustre · Neuropsychopharmacology2003PDF347 KB
P.6.d.007 The Selective Nicotinic Alpha7 Receptor Agonist SSR180711 Does Not Induce Locomotor SensitisationMirza · European Neuropsychopharmacology2007PDF68 KB
SSR181507, a Dopamine D2 Receptor and 5-HT1A Receptor Ligand: Evidence for Mixed Anxiolytic- and Antidepressant-like ActivitiesBoulay · Pharmacology Biochemistry and Behavior2011PDF586 KB
Partial Agonist Properties of the Antipsychotics SSR181507, Aripiprazole and Bifeprunox at Dopamine D2 Receptors: G Protein Activation and Prolactin ReleaseCosi · European Journal of Pharmacology2006PDF473 KB